Sanofi S.A., FR0000120578

Jefferies keeps Buy rating for Sanofi stock at EUR 100 target

Published on 10/09/2026 at 12:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter sales rose 17.80 percent to EUR 11.60 billion for Sanofi. Sanofi stock costs EUR 71.59 on October 9, 2026 after EUR 71.78.

Key points in brief

Jefferies kept a Buy rating and EUR 100.00 target for Sanofi on October 6, 2026.
Sanofi and Regeneron expanded their antibody alliance with a USD 1.00 billion upfront payment and up to USD 7.00 billion in milestones.
Second-quarter 2026 net sales rose 17.80 percent to EUR 11.60 billion, while Dupixent sales grew 37.00 percent.
Sanofi stock was EUR 71.59 at Lang & Schwarz on October 9, 2026, down 0.26 percent from EUR 71.78.

Modern pharmaceutical sterile fill-and-finish manufacturing facility interior with glass vial-filling machines and cleanroom workers in white suits — Sanofi FR0000120578 photorealistic sterile fill-and-finish facility with vial-filling machines and cleanroom workers, Illustration mit AI erstellt.

Sanofi (ISIN FR0000120578) had a EUR 100.00 price target and Buy rating from Jefferies in a note dated October 6, 2026. The analyst cited scope for a modest third-quarter beat and a higher 2026 sales outlook, while warning that acquisitions remain important as Dupixent approaches patent pressure.

What does the alliance add?

Sanofi and Regeneron expanded their antibody alliance on October 1, 2026, adding four long-acting immunology candidates. According to Sanofi, the agreement requires a USD 1.00 billion upfront payment and allows up to an additional USD 7.00 billion in milestone payments.

The companies will split development and commercialization costs and future profits equally for the new programs. The arrangement also settles earlier collaboration litigation, but the candidates remain at early development stages, leaving clinical and regulatory execution as the key financial test.

Sanofi's recent milestones

On September 18, 2026, second-quarter net sales increased 17.80 percent year over year to EUR 11.60 billion, according to ScanX. Dupixent sales exceeded EUR 5.00 billion and rose 37.00 percent, while business earnings per share grew 33.30 percent.

On October 6, 2026, Jefferies kept its Buy rating and EUR 100.00 target, as T-Online reported. The target is EUR 28.41 above the Lang & Schwarz price of EUR 71.59, equal to 39.69 percent upside on a same-currency comparison.

Upcoming reporting dates

Sanofi's investor calendar lists third-quarter 2026 results for October 30, 2026, followed by fourth-quarter and full-year 2026 results on January 28, 2027, according to Sanofi. The October report will show whether Dupixent growth and new-product launches offset seasonal vaccine pressure.

Stock stays below the analyst target

Sanofi was trading at EUR 71.59 at Lang & Schwarz on October 9, 2026 at 12:40 p.m. CEST, down 0.26 percent versus the prior close of EUR 71.78. The company had a market capitalization of EUR 86.7 billion on Euronext Paris on October 9, 2026, while its primary listing is in the CAC 40.

The further course of trading is shown by the continuously updated real-time quote of Sanofi stock.